DOCSLIB.ORG

Three Levels: 3 – Specific Medication Options Considerations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Three Levels: 3 – Specific Medication Options Considerations PRESCRIBING FOR BEHAVIOR: Three Levels: HOW DO YOU DECIDE? 1. Is patient/diagnosis likely to respond to medication? Christopher Pachel, 2. Maintenance/daily vs. Situational/event? DVM, DACVB, CABC Animal Behavior Clinic Portland, Oregon 3. Specific medication options 1 2 1 - Likely to respond to meds? 2 - Treatment focus: (Yes or No) (Maintenance vs. Situational) Diagnoses: Maintenance/daily Fear/Anxiety Triggers are frequent, unpredictable, unavoidable Onset of action from 1-3 to 4-6 weeks Impulsivity/Arousal “Steady state” effect Aggression (motivated by anxiety, impulsivity, etc.) Compulsive disorder Situational/event Urine marking Triggers are predictable, infrequent Adjunctive support Onset of action from 15 min to 1-2 hours In combination with: Rapid adjustment of doses within trial period Safety/management Short duration of action (potential for “scalloped” effect) Behavior modification 3 4 3 – Specific medication options Considerations Patient/Diagnosis likely Treatment focus? Specific options: Medications FDA approved to respond to medication? for use in dogs (NONE in cats) Maintenance Fluoxetine Paroxetine Clomicalm® (clomipramine) – Sertraline Clomipramine Separation anxiety Yes Reconcile ® (fluoxetine) – Situational/Event Trazodone Clonidine Separation anxiety Benzodiazepines (5) Anipryl® (selegiline) – CDS Acepromazine and PDH Other/Adjunctive Gabapentin No Buspirone Sileo® (dexmedotomidine) – Amitriptyline Noise aversion 5 6 1 Neurotransmitters / Intended Impact 3a – Favorite maintenance medications Patient/DiagnosisSSRI likely Treatment focus? Specific options: Amino acids: to respond to medication? Fluoxetine Fluoxetine Glutamate: excitatory Maintenance Paroxetine Paroxetine GABA: inhibitory Sertraline Sertraline Clomipramine Yes Situational/Event Trazodone Biogenic amines: Clonidine TCA Benzodiazepines (5) Serotonin (5HT) Acepromazine Clomipramine Other/Adjunctive Dopamine (DA) Gabapentin Buspirone Norepinephrine (NE) Amitriptyline 7 8 On to cases! Milo (13yr m/n Maine Coon) Primary concern: urination outside of box, spraying, aggression toward other cat (MK) Four cats total in home (two residents - Milo and Max, two new - MK and Murphy) Daily frequency of urine soiling, combination of horizontal and vertical Reliable use of boxes for defecation 9 10 Milo (13yr m/n Maine Coon) Milo (13yr m/n Maine Coon) Previous use of Feliway diffusers, minor impact on Dx: Urine marking (vertical +/- horizontal locations) frequency of soiling Toileting / Inappropriate elimination (horizontal locations) Multi-level home, unstable household routines (owner Intercat aggression travel schedule) Tx: Household mgmt. (separation when unsupervised, journal soiling Medical workup - no significant findings details, enzymatic cleaner, ongoing Feliway use) Increased availability of household resources Use of deterrents (foil, block access, etc.) - no Clicker training for litter box use impact on frequency Zylkene trial (reluctance to use medication initially) Improvement in frequency at 10-12 weeks, but ongoing soiling 11 12 2 Three Levels: “Milo” Fluoxetine 1. Is patient/diagnosis likely to respond to Generic/inexpensive medication? Lots of anecdotal experience within the profession Impulsivity/arousal as focus for treatment, also for fear/anxiety Available research (“dominance aggression”, urine 2. Maintenance/daily vs. Situational/event? marking, separation anxiety – as Reconcile) Negative impact on appetite Pro – resource guarding, competitive aggression, food related arousal 3. Specific medication options Con – anorexia, client perception 13 14 Paroxetine Sertraline Generic/inexpensive Not quite as inexpensive, but generally affordable Generally less of an impact on appetite than Smallest tablet size is 25mg (may require fluoxetine (similar indications) compounding for cats and small dogs) More of an anticholinergic profile than fluoxetine Social anxiety, less impact on arousal/impulsivity Helpful for patients with chronic/situational loose unless at higher end of dose range bowels, urinary incontinence Less likely to cause side effects (sedation, anorexia, Potential for dry mouth and/or constipation constipation, etc.) 15 16 Clomipramine / Clomicalm “Pebbles” (11 mos Chesapeake B.R.) Impact on both serotonin and norepinephrine Primary concern: aggression toward other dog My medication of choice when both (14yr m/n lab mix, Ben) over food impulsivity/arousal and anxiety impact is desired Onset ~6 months old, progressively worsening Significantly more expensive (intensity/frequency, speed of escalation) Generic/compounded, Clomicalm Deferential postures by Ben, lack of appropriate Anticholinergic side effect profile de-escalation by Pebbles Sedation not uncommon especially as getting started Superficial injuries to Ben (significant stress/fear) with treatment 17 18 3 “Pebbles” (11 mos Chesapeake B.R.) “Pebbles” (11 mos Chesapeake B.R.) No history of aggression at dog park or daycare Lack of response to interventions (walk away, call away, sweet talk, reprimand) Generally "inflexible", “Police Officer Pebbles" Solid obedience/manners training, moderately structured household 19 20 “Pebbles” (11 mos Chesapeake B.R.) Three Levels: “Pebbles” Dx: 1. Is patient/diagnosis likely to respond to Resource guarding / competitive aggression (relationship specific) medication? Generalized anxiety (mild, underlying influence on behavior) Tx: Leadership program 2. Maintenance/daily vs. Situational/event? Basket muzzle training "Feeling outnumbered" strategies (incl. “belle of the ball”) Proactive mgmt/avoidance of triggers, intervention strategies Body language awareness 3. Specific medication options Physical exercise 21 22 “Silas” (3yr m/n GSD) “Silas” (3yr m/n GSD) Primary concerns: fearful of people, objects, trees, Hypervigilant in public cars; aggressive toward some dogs Refuses food when overly aroused/stressed 18 months in home (10th home / 2 years) Defecates 4x/day, softer stools with daily stress Onset within 6 weeks of adoption (also with prior Attempts at "desensitization" border on "flooding“ owners) Walked 1-3 hours/day, 6 mile runs with owner Variable reaction to other dogs (n/r to "ballistic") 23 24 4 “Silas” (3yr m/n GSD) “Silas” (3yr m/n GSD) Dx: Fear based behaviors (worse on leash, neophobia) Generalized anxiety (hypervigilance, startle reactions) Territorial/protective behavior (minor, opportunity based) Breed specific patterns (GSD), Insufficient socialization (presumed) Tx: Shift in training style (limit of obedience/suppression) Behavior modification (relaxation, movement cues, DSCC to triggers) Proactive avoidance / recovery strategies / no rehearsal Body language awareness (threshold!) Phase out use of e-collar (as skill set improves) 25 26 Three Levels: “Silas” SSRI/TCA 1. Is patient/diagnosis likely to respond to Dosages (oral administration): medication? Canine Feline Fluoxetine (Prozac®) 1-2 mg/kg q24hr 0.5-1.0 mg/kg q24hr 2. Maintenance/daily vs. Situational/event? Paroxetine (Paxil®) 1-2 mg/kg q24hr 0.5-1.0 mg/kg q24hr (q12hr instead?) Sertraline (Zoloft®) 1-3 mg/kg q24hr 0.5 mg/kg q24hr (q12hr instead?) Clomipramine (Clomicalm®) 1-3 mg/kg q12hr 0.3-0.5 mg/kg q24hr 3. Specific medication options 27 28 “Mabel” (4yr female French bulldog) “Mabel” (4yr female French bulldog) Primary concerns: separation anxiety (from Steve), Able to be kenneled when home alone, no self fear of strangers, aggression toward owner (Ron) injury or environmental destruction Recently adopted, breeder from puppy mill Limited training (attempted classes, unable to make More likely to aggress toward Ron when resting on progress in class or at home) couch with Steve, otherwise fearful/avoidant of Ron Occasional soiling when at home with Ron (unable Snapping >>> biting (one bite with contact, no to get her outside vs. anxiety) injury) “Back injury” – no evidence of pain/discomfort 29 30 5 “Mabel” (4yr female French bulldog) Three Levels: “Mabel” Dx: 1. Is patient/diagnosis likely to respond to Fear based behaviors (impact of undersocialization) medication? Separation anxiety Resource guarding Tx: BMod (clicker training, sit, eye contact, hand targeting) 2. Maintenance/daily vs. Situational/event? Relationship building (awareness of body language, mark/reward engagement) Calm departures/greetings (Steve) Zylkene trial (reluctant to use medication) Insufficient response to treatment at 10-12 weeks 3. Specific medication options 31 32 "Riley" (5yr f/s Springer spaniel mix) "Riley" (5yr f/s Springer spaniel mix) Primary concerns: target of aggression by other Owners have limited training experience, slow to dog, unable to confine elsewhere in home, unable to acquire training skills train due to stress level Able to manage both dogs during normal daily Recently acquired by family, one other dog in home, routine, support needed for household gatherings Riley is target of competitive aggression (2-3 per year) Infrequent visitors to home, noises from household Short trial of fluoxetine, "zoned out", discontinued activity more likely to trigger arousal/barking than Previous use of alprazolam/acepromazine, is separation/isolation inconsistent response to combination 33 34 "Riley" (5yr f/s Springer spaniel mix) Three Levels: “Riley” Dx: 1. Is patient/diagnosis likely to respond to Separation anxiety (separation affects tolerance for other stressors) medication? Social/situational anxiety (affects response to training
Load more

Recommended publications
  • Switching from Clonidine Immediate-Release to Guanfacine Extended-Release
    / DE L’ACADÉMIE CANADIENNE DE PSYCHIATRIE DE L’ENFANT ET DE L’ADOLESCENT PSYCHOPHARMACOLOGY Switching from Clonidine Immediate-Release to Guanfacine Extended-Release Dean Elbe PharmD, BCPP1,2,3 s a clinical pharmacy specialist in child and adolescent (Canada) Ltd, 2012b). Clonidine has been used off-label Amental health, I am frequently asked how to switch in children for many years for treatment of insomnia, patients from clonidine immediate-release (IR) to guanfa- ADHD, and disruptive behaviour disorders (Hunt, Capper cine extended-release (XR). This therapeutic switch may be & O’Connell, 1990; Rubinstein; Jaselskis, Cook, Fletcher required when poor adherence to a clonidine IR regimen & Leventhal, 1992; Silver & Licamele, 1994; Palumbo et (typically requiring 3–4 doses daily) is identified, when al., 2008; Efron, Lycett & Sciberras, 2014). A clonidine XR clonidine dose-optimization is limited by sedation, brady- formulation is not available in Canada, but is available in cardia or hypotension, or when coverage situations change. the United States for treatment of ADHD (Concordia Phar- The latter may occur if, for example, new eligibility for a maceuticals, Inc. 2015). government program or a third party-payer occurs. Weight-based dosing guidelines exist for clonidine IR Guanfacine XR, a selective alpha2A agonist, was first mar- (0.003–0.008 mg/kg/day) and guanfacine XR (0.05–0.08 keted in Canada in late 2013 for the treatment of attention mg/kg/day) (Shire Pharma Canada ULC, 2019; Elbe et deficit hyperactivity disorder (ADHD) in children and ado- al., 2018). Based on these guidelines and other literature, lescents (Shire Pharma Canada ULC, 2019).
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Memory Deficits Associated with Clonidine
    Letter to the Editor Letters to the Editor are invited for comment on a topic of current interest or on Table material published in GENERAL HOSPITAL PSYCHIATRY. Letters should be typed doubled spaced and are subject to editing according to space limitations. - Memory Deficits Associated with Attent KnO Clonidine WA Verbal WA Drugs used in the treatment of essential hyperten- Initiation of clonidine therapy (0.1 mg b.i.d.) in WA sion are among the most commonly prescribed. April 1984 resulted in well-controlled hypertension Tactilc Some of these agents have primary effects on neu- without immediately apparent adverse effects. Fulc rotransmitter systems and are centrally active. However, the coincidence of the onset of memory Verba Thus, drugs such as a-methyldopa, propranalol, complaints and the beginning of clonidine treat- 3% ment suggested that clonidine might be respon- List Ll and reserpine have well-established neuropsychia- Fulc tric complications, ranging from depression to cog- sible. si nitive impairments and psychosis [l].Since the use After consultation with the patient's internist, a R of these drugs is widespread and unavoidable, we switch was made to captopril, an angiotensin-con- T must be alert to the possibility that these drugs verting enzyme inhibitor. Before the change we T administered tests of attention, concentration, and contribute to psychologic complaints and symp- -R toms of our patients. verbal skills as well as the Fuld Object-Memory Evaluation, which includes a measure of verbal 'Age-a Clonidine, a presynaptic adrenergic a2agonist, bNonc has become well established as a useful and rela- fluency as well as a selective reminding list learning tively safe therapeutic agent.
    [Show full text]
  • Sleep & Dreams & Dsm-5
    PAL Conference - Green River, WY - May 2015 SLEEP & DREAMS & DSM-5: ASSESSMENT AND TREATMENT OF PEDIATRIC INSOMNIA James Peacey, MD PAL Conference Green River, WY Disclosure Statement No relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in this CME activity. I will reference off-label or investigational use of medications in this presentation. PAL Conference - Green River, WY - May 2015 Goals and Objectives Learn how to identify and categorize pediatric insomnia. Increase knowledge of common behavioral and pharmacologic sleep treatments. Increase understanding of sleep issues in particular patient populations (Autism, ADHD, depression and anxiety) and appropriate strategies to optimize treatment. PAL Conference - Green River, WY - May 2015 Sleep Stage Development PAL Conference - Green River, WY - May 2015 Homeostatic and Circadian Processes D. J. Dijk and D. M. Edgar, Regulation of Sleep and Wakefulness, 1999 PAL Conference - Green River, WY - May 2015 Homeostatic and Circadian Processes PAL Conference - Green River, WY - May 2015 Alerting Systems PAL Conference - Green River, WY - May 2015 Normal Sleep Requirements Babcock, Pediatr Clin N Am 58 (2011) 543–554PAL Conference - Green River, WY - May 2015 Percentiles for total sleep duration per 24 hours from infancy to adolescence. Iglowstein I et al. Pediatrics 2003;111:302-307 PAL Conference - Green River, WY - May 2015 ©2003 by American Academy of Pediatrics Insomnia “significant difficulty initiating
    [Show full text]
  • Acepromazine
    Acepromazine Background Acepromazine is a phenothiazine derivative widely used in equine veterinary medicine for mild sedation.i It is assigned a 3/B classification by the ARCI. Acepromazine can also be used as part of a pre- anesthetic protocol for surgical procedures. Acepromazine is a prescription medication and can only be dispensed from, or upon the request of, a veterinarian. Common trade names for acepromazine include AceproJect™ and PromAce™. Generic versions are also available. It is commercially available in "Acepromazine structure" by Emeldir (talk) - injectable (intravenous and intramuscular) and tablet Own work. Licensed under Public Domain via formulations. Historically, acepromazine was not Commons - recommended for use in intact stallions due to risk of https://commons.wikimedia.org/wiki/File:Ace promazine_200.svg prolonged penile prolapse. However, the most recent data suggest this risk is quite low, and many anesthesiologists use this as a pre-anesthetic medication, even in intact stallions.ii Acepromazine’s specific mechanism of action is poorly understood. Proposed mechanisms include central depression through dopaminergic pathways and peripheral actions including action on cholinergic, histaminergic, and adrenergic receptors. Administration Studies Intravenous Administration – Therapeutic Dose Acepromazine (Acepromazine, generic 10 mg/mL solution from Webster Pharmacy) was administered to twenty exercise-conditioned Thoroughbred horses (geldings and mares) housed at the University of Florida Equine Pharmacokinetics Laboratory. Each horse received a one-time 0.05 mg/kg dose via intravenous injection. Blood samples were obtained immediately prior to medication administration and at the following times: 5, 10, 15, 20, 30, and 45 minutes; and 1, 2, 3, 4, 6, 8, 24, and 48 hours post- administration.
    [Show full text]
  • Kentucky Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred; Quarter Horse, Appaloosa, and Arabian KHRC 8-020-2 (11/2018)
    Kentucky Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred; Quarter Horse, Appaloosa, and Arabian KHRC 8-020-2 (11/2018) General Notice Unless otherwise specified in these withdrawal guidelines or the applicable regulations and statutes, the following withdrawal guidelines are voluntary and advisory. The guidelines are recommendations based on current scientific knowledge that may change over time. A licensee may present evidence of full compliance with these guidelines to the Kentucky Horse Racing Commission (the “Commission” or “KHRC”) and the stewards as a mitigating factor to be used in determining violations and penalties. These withdrawal interval guidelines assume that administration of medications will be performed at doses that are not greater than the manufacturer’s maximum recommended dosage. Medications administered at dosages above manufacturer’s recommendations, in compounded formulations and/or in combination with other medications and/or administration inside the withdrawal interval may result in test sample concentrations above threshold concentrations that could lead to positive test results and the imposition of penalties. The time of administration of an orally administered substance, for the purposes of withdrawal interval, shall be considered to be the time of complete ingestion of the medication by the horse via eating or drinking. Brand names of medications, where applicable, are listed in parentheses or brackets following the generic name of a drug. In addition to the requirements contained in KRS Chapter 13A, the KHRC shall give notice of an amendment or addition to these withdrawal guidelines by posting the change on the KHRC website and at all Kentucky racetracks at least two weeks before the amendment or addition takes legal effect.
    [Show full text]
  • Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: a Literature Review
    medical sciences Review Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: A Literature Review Sachin Relia 1,* and Vijayabharathi Ekambaram 2,* 1 Department of Psychiatry, University of Tennessee Health Sciences Center, 920, Madison Avenue, Suite 200, Memphis, TN 38105, USA 2 Department of Psychiatry, University of Oklahoma Health Sciences Center, 920, Stanton L Young Blvd, Oklahoma City, OK 73104, USA * Correspondence: [email protected] (S.R.); [email protected] (V.E.); Tel.: +1-901-448-4266 (S.R.); +1-405-271-5251 (V.E.); Fax: +1-901-297-6337 (S.R.); +1-405-271-3808 (V.E.) Received: 15 August 2018; Accepted: 17 October 2018; Published: 25 October 2018 Abstract: Autism is a developmental disability that can cause significant emotional, social and behavioral dysfunction. Sleep disorders co-occur in approximately half of the patients with autism spectrum disorder (ASD). Sleep problems in individuals with ASD have also been associated with poor social interaction, increased stereotypy, problems in communication, and overall autistic behavior. Behavioral interventions are considered a primary modality of treatment. There is limited evidence for psychopharmacological treatments in autism; however, these are frequently prescribed. Melatonin, antipsychotics, antidepressants, and α agonists have generally been used with melatonin, having a relatively large body of evidence. Further research and information are needed to guide and individualize treatment for this population group. Keywords: autism spectrum disorder; sleep disorders in ASD; medications for sleep disorders in ASD; comorbidities in ASD 1. Introduction Autism is a developmental disability that can cause significant emotional, social, and behavioral dysfunction. According to the Diagnostic and Statistical Manual (DSM-V) classification [1], autism spectrum disorder (ASD) is characterized by persistent deficits in domains of social communication, social interaction, restricted and repetitive patterns of behavior, interests, or activities.
    [Show full text]
  • Data Sheet SURMONTIL Trimipramine (As Maleate) 25 Mg Tablets and 50 Mg Capsules
    Data Sheet SURMONTIL trimipramine (as maleate) 25 mg tablets and 50 mg capsules Presentation SURMONTIL tablets are compression coated, white or cream, circular, biconvex, containing the equivalent of 25mg trimipramine (as maleate) with a diameter of about 8.0mm. The face is indented with the name and strength, reverse plain. SURMONTIL capsules are opaque white with opaque green cap, printed SU50, each containing the equivalent of 50mg trimipramine (as maleate). Uses Actions SURMONTIL has a potent anti-depressant action similar to that of other tricyclic anti-depressants. The mechanism of action is not fully understood but it is thought to be via inhibition of neuronal re- uptake of noradrenalin, thereby increasing availability. SURMONTIL also possesses a pronounced sedative action. Pharmacokinetics SURMONTIL is readily absorbed after oral administration, reaching a mean peak plasma level after 3 hours. High first pass hepatic clearance results in a mean bioavailability of about 41% of the oral dose, and trimipramine is extensively protein bound in plasma. Elimination half-life is 24 hours. Metabolism is in the liver to its major metabolite, desmethyltrimipramine, which is excreted mainly in the urine. Indications SURMONTIL is indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety or agitation is a presenting symptom. Sleep disturbance is controlled within 24 hours and true anti-depressant action follows within 7-10 days. Dosage and Administration Adults Mild/Moderate Depression in General Practice: The recommended dosage is 50-75 mg orally given two hours before bedtime, the larger dose (75 mg) being preferable for those patients with more marked sleep disturbance.
    [Show full text]
  • Effects of Sympathetic Inhibition on Receptive, Proceptive, and Rejection Behaviors in the Female Rat
    Physiology & Behavior, Vol. 59, No. 3, pp. 537-542, 1996 Copyright © 1996 Elsevier Science Inc. Printed in the USA. All rights reserved 0031-9384/96 $15.00 + .00 ELSEVIER 0031-9384(95)02102-2 Effects of Sympathetic Inhibition on Receptive, Proceptive, and Rejection Behaviors in the Female Rat CINDY M. MESTON, 1 INGRID V. MOE AND BORIS B. GORZALKA Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver, British Columbia, Canada V6T 1Z4 Received 27 September 1994 MESTON, C. M., I. V. MOE AND B. B. GORZALKA. Effects of sympathetic inhibition on receptive, proceptive, and rejection behaviors in the female rat. PHYSIOL BEHAV 59(3) 537-542, 1996.--The present investigation was designed to examine the effects of sympathetic nervous system (SNS) inhibition on sexual behavior in ovariec- tomized, steroid-treated female rats. Clonidine, an alpha2-adrenergic agonist, guanethidine, a postganglionic noradren- ergic blocker, and naphazoline, an alpha2-adrenoreceptor agonist were used to inhibit SNS activity. Intraperitoneal injections of eit:aer 33/zg/ml or 66/xg/ml clonidine significantly decreased receptive (lordosis) and proceptive (ear wiggles) behaviors and significantly increased rejection behaviors (vocalization, kicking, boxing). Either 25 mg/ml or 50 mg/ml guanethidine significantly decreased receptive and proceptive behavior and had no significant effect on rejection behav!iors. Naphazoline significantly inhibited lordosis behavior at either 5 mg/ml or 10 mg/ml doses, significantly inhibited proceptive behavior at 5 mg/ml, and had no significant effect on rejection behaviors. These findings supporc the hypothesis that SNS inhibition decreases sexual activity in the female rat. Lordosis Proceptive behavior Rejection behavior Clonidine Guanethidine Naphazoline Alpha-adrenergic INTRODUCTION as 2 /xg/animal also inhibits lordosis behavior (1).
    [Show full text]
  • Acepromazine Injection(Acepromazine Maleate Injection)
    ACEPROMAZINE MALEATE- acepromazine maleate injection MWI/VetOne ---------- Acepromazine Injection (acepromazine maleate injection) Approved by FDA under NADA # 015-030 Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Description: Acepromazine Injection, a potent neuroleptic agent with a low order of toxicity, is of particular value in the tranquilization of dogs, cats and horses. Its rapid action and lack of hypnotic effect are added advantages. According to Baker,1 the scope of possible applications for this compound in veterinary practice is only limited by the imagination of the practitioner. Each mL contains: acepromazine maleate 10 mg, sodium citrate 0.36%, citric acid 0.075%, benzyl alcohol 1% and water for injection. Acepromazine [10-[3-(dimethyl-amino) propyl] phenothiazin-2-yl-methyl ketone] Maleate, USP has the following chemical structure: Acepromazine Injection has a depressant effect on the central nervous system and, therefore, causes sedation, muscular relaxation and a reduction in spontaneous activity. It acts rapidly, exerting a prompt and pronounced calming effect. Indications: Dogs and Cats: Acepromazine Injection can be used as an aid in controlling intractable animals during examination, treatment, grooming, x-ray and minor surgical procedures; to alleviate itching as a result of skin irritation; as an antiemetic to control vomiting associated with motion sickness. Acepromazine Injection is particularly useful as a preanesthetic agent (1) to enhance and prolong the effects of barbiturates, thus reducing the requirements for general anesthesia; (2) as an adjunct to surgery under local anesthesia. Horses: Acepromazine Injection can be used as an aid in controlling fractious animals during examination, treatment, loading and transportation.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]